Estramustine Phosphate Versus Placebo as Second Line Treatment After Orchiectomy in Patients With Metastatic Prostate Cancer: Daproca Study 9002
- 1 March 1997
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 157 (3), 929-934
- https://doi.org/10.1016/s0022-5347(01)65086-9
Abstract
No abstract availableThis publication has 18 references indexed in Scilit:
- Mitomycin C Versus Estramustine in the Treatment of Hormone Resistant Metastatic Prostate Cancer: Thefinal Analysis of the European Organization Forresearch and Treatment of Cancer, Genitourinarygroup Prospective Randomized Phase III Study (30865)Journal of Urology, 1993
- The Management of Carcinoma of the Prostate after Failed Primary TherapyBritish Journal of Urology, 1993
- Evidence for a non-estrogenic cytostatic effect of estramustine on human prostatic carcinoma cells in vivoThe Prostate, 1992
- Hormone-Resistant Metastatic Prostate CancerEuropean Urology, 1991
- Estramustine binds a MAP-1-like protein to inhibit microtubule assembly in vitro and disrupt microtubule organization in DU 145 cells.The Journal of cell biology, 1988
- Comparison of flutamide and emcyt in hormone-refractory metastatic prostatic cancerUrology, 1988
- Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate?Journal of Clinical Oncology, 1985
- Cytotoxic properties of estramustine unrelated to alkylating and steroid constituentsUrology, 1984
- Treatment of Stage D Hormone-Resistant Carcinoma of the Prostate with Estramustine PhosphateJournal of Urology, 1979
- Treatment of Advanced Prostatic Carcinoma with Estramustine Phosphate (Estracyt®)Scandinavian Journal of Urology and Nephrology, 1977